| Code | CSB-RA001950MB11HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to PRX-012, targeting the amyloid precursor protein (APP). APP is a type I transmembrane glycoprotein that plays critical roles in neuronal development, synaptic plasticity, and cell adhesion. Through sequential proteolytic cleavage by β- and γ-secretases, APP generates amyloid-beta (Aβ) peptides, which aggregate to form the characteristic amyloid plaques found in Alzheimer's disease. Dysregulation of APP processing and accumulation of Aβ species are central pathological features of Alzheimer's disease and are implicated in neurodegeneration, making APP a crucial target for understanding disease mechanisms.
PRX-012 is a reference antibody designed to recognize specific epitopes of APP or its cleavage products, facilitating research into amyloid pathology and APP metabolism. This biosimilar provides researchers with a reliable tool for investigating APP expression, processing pathways, and the role of amyloid-beta in neurodegenerative disorders. It supports studies examining therapeutic strategies targeting amyloid cascade mechanisms and enables exploration of APP's physiological functions in neuronal health and disease progression.
There are currently no reviews for this product.